# Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

> **NCT04335292** · PHASE2 · RECRUITING · sponsor: **Mark Vincent** · enrollment: 200 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib First-Line
- **DRUG:** Platinum + Pemetrexed Chemotherapy Second-Line
- **DRUG:** Osimertinib Third-Line

## Key facts

- **NCT ID:** NCT04335292
- **Lead sponsor:** Mark Vincent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-06
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04335292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04335292, "Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04335292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*